Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11884125 | 0.81 | MAPT (0.47) | KDM4EKMT2AGLAMEN1USP2 | |
| SCHEMBL11826941 | 0.81 | MMP2 (0.41) | KDM4EKMT2AGLAMEN1USP2 | |
| SCHEMBL11800551 | 0.81 | HPGD (0.49) | KDM4EKMT2AGLAMEN1USP2 | |
| SCHEMBL2069450 | 0.80 | MMP2 (0.45) | KDM4EKMT2AGLAMEN1USP2 | |
| SCHEMBL10643031 | 0.77 | MMP2 (0.42) | KDM4EKMT2AGLAMEN1USP2 | |
| SCHEMBL11826853 | 0.77 | MMP2 (0.42) | KDM4EKMT2AGLAMEN1USP2 | |
| SCHEMBL3293364 | 0.75 | MMP2 (0.46) | KDM4EKMT2AGLAMEN1USP2 | |
| SCHEMBL11838205 | 0.75 | MMP2 (0.40) | KDM4EKMT2AGLAMEN1USP2 | |
| SCHEMBL2464183 | 0.74 | RAB9A (0.62) | KDM4EKMT2AMEN1GAAHPGD | |
| SCHEMBL18876477 | 0.73 | MMP2 (0.50) | KDM4EKMT2AMEN1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362451-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017097234-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-06-15 | — | — | WO | disclosed |
| EP-1335907-B1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB PUBL (SE) | 2010-06-09 | — | — | EP | disclosed |
| CN-100451016-C | Piperazinylpyrazine compounds as agonists or antagonists of serotonin 5ht-2 receptors | BIOVITRUM AB (SE) | 2009-01-14 | — | — | CN | disclosed |
| US-7247633-B2 | Pyrimidine compounds and their use | BIOVITRUM AB (SE) | 2007-07-24 | — | — | US | disclosed |
| CN-1876648-A | Piperazinylpyrazine compounds as agonists or antagonists of serotonin 5ht-2 receptors | BIOVITRUM AB (SE) | 2006-12-13 | — | — | CN | disclosed |
| CN-1267424-C | Piperazinylpyrazine compounds as agonists or antagonists of the 5-hydroxytryptamine 5 HT-2 receptor | BIOVITRUM AB (SE) | 2006-08-02 | — | — | CN | disclosed |
| CN-1479727-A | Piperazinylpyrazine compounds as agonists or antagonists of the 5-hydroxytryptamine 5 HT-2 receptor | �Ȱ�ά����ķ�ɷݹ�˾ | 2004-03-03 | — | — | CN | disclosed |
| US-20040014767-A1 | Novel compounds and their use | BIOVITRUM AB, A SWEDISH CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-6593330-B2 | Central nervous system disorders; antiserotonine agents | BIOVITRUM (SE) | 2003-07-15 | — | — | US | disclosed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147200-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | KDM4E 1971/4885KMT2A 1705/4885GLA 508/4885 |
| US-20040014767-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | KDM4E 1971/4885KMT2A 1705/4885GLA 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.